"10.1371_journal.pone.0010496","plos one","2010-05-05T00:00:00Z","Adam D Bachstetter; Jennifer Jernberg; Andrea Schlunk; Jennifer L Vila; Charles Hudson; Michael J Cole; R Douglas Shytle; Jun Tan; Paul R Sanberg; Cyndy D Sanberg; Cesario Borlongan; Yuji Kaneko; Naoki Tajiri; Carmelina Gemma; Paula C Bickford","Department of Molecular Pharmacology and Physiology, College of Medicine, University of South Florida, Tampa, Florida, United States of America; Department of Neurosurgery and Brain Repair, Center of Excellence for Aging and Brain Repair, College of Medicine, University of South Florida, Tampa, Florida, United States of America; James A. Haley Veterans Administration Hospital, Research Service, Tampa, Florida, United States of America; Department of Psychiatry, College of Medicine, University of South Florida, Tampa, Florida, United States of America; NaturaTherapeutics, Incorporated, Tampa, Florida, United States of America","Conceived and designed the experiments: ADB RDS JT PS CDS CG PCB. Performed the experiments: ADB JJ AS JV CEH MJC YK NT CG. Analyzed the data: ADB CVB YK CG PCB. Wrote the paper: ADB CG PCB.","PCB and PRS are founders of NaturaTherapeutics, Inc., and have consulting relationship but no employment with NaturaTherapeutics, Inc.; JT and RDS are consultants for NaturaTherapeutics, Inc. NT-020 is a patented formulation that is marketed by NaturaTherapeutics, Inc. The patent is held by CDS, PB, JT, RDS, PRS, the University of South Florida and the Veterans Administration. CDS is employed by NaturaTherapeutics, Inc. These relationships do not alter adherence to all the PLoS ONE policies on sharing data and materials.","2010","05","Adam D Bachstetter","ADB",15,TRUE,7,9,5,3,TRUE,TRUE,FALSE,0,NA,FALSE
